Minimum target prices for production of direct‐acting antivirals and associated diagnostics to combat hepatitis C virus-Reference-Cited by-同舟云学术

Minimum target prices for production of direct‐acting antivirals and associated diagnostics to combat hepatitis C virus

Published:2015-02-09 Issue:4 Volume:61 Page:1174-1182
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

van de Ven Nikolien¹,Fortunak Joe²,Simmons Bryony¹,Ford Nathan³,Cooke Graham S.¹,Khoo Saye⁴,Hill Andrew⁴

Affiliation:

1. Division of Infectious DiseasesImperial College London London United Kingdom

2. Chemistry and Pharmaceutical SciencesHoward UniversityWashington DC

3. Center for Infectious Disease Epidemiology and ResearchUniversity of Cape Town South Africa

4. Department of Pharmacology and TherapeuticsLiverpool University Liverpool United Kingdom

Funder

UNITAID

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.27641

Reference52 articles.

1. World Health Organisation.Hepatitis C fact sheet. Updated April 2014. Available at:http://www.who.int/mediacentre/factsheets/fs164/en/. Accessed May 10 2014.

2. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence

3. LondeixP ForetteC.New treatments for hepatitis C virus: strategies for achieving universal access. Médecins du Monde. 2014. Available at:http://www.hepcoalition.org/IMG/pdf/daas_strategies_for_achieving_universal_access_en.pdf. Accessed May 10 2014.

4. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals

5. Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daclatasvir as a hepatitis C infection treatment option: an up-to-date evaluation;Expert Opinion on Pharmacotherapy;2022-11-17

2. Current prices versus minimum costs of production for CFTR modulators;Journal of Cystic Fibrosis;2022-09

3. Breakthroughs in hepatitis C research: from discovery to cure;Nature Reviews Gastroenterology & Hepatology;2022-05-20

4. Worldwide rates of diagnosis and effective treatment for cystic fibrosis;Journal of Cystic Fibrosis;2022-05

5. Cost-utility analysis of four WHO-recommended sofosbuvir-based regimens for the treatment of chronic hepatitis C in sub-Saharan Africa;BMC Health Services Research;2022-03-05